Beam Therapeutics Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- John Evans
- Full Time Employees
- 540
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 238 Main Street Cambridge MA United States of America 02142
- IPO Date
- Feb 6, 2020
- CIK
- 0001745999
- Website
- beamtx.com
- Similar Companies
- Business
- Beam Therapeutics Inc. (Nasdaq: BEAM) develops precision genetic medicines through proprietary base editing technologies that enable targeted single-nucleotide changes in DNA without double-strand breaks; core pipeline programs include BEAM-101 for sickle cell disease and beta-thalassemia, BEAM-302 for severe alpha-1 antitrypsin deficiency (AATD), BEAM-201 for refractory T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL), BEAM-301 for glycogen storage disease 1a (GSDIa), and BEAM-103/104 for additional genetic diseases; delivery platforms encompass electroporation, non-viral lipid nanoparticles, and viral modalities. Founded in 2017 and headquartered at 238 Main Street in Cambridge, Massachusetts, with a manufacturing facility in Research Triangle Park, North Carolina, the company targets serious diseases in hematology, liver, oncology, and genetic disease segments, primarily in the United States. Recent developments include FDA clearance for the BEAM-301 IND in GSDIa, dosing of the first patient in the BEAM-302 Phase 1/2 trial for AATD, enrollment of over 20 patients with six dosed in the BEACON Phase 1/2 trial for BEAM-101 in severe sickle cell disease, acquisition of an early-stage life sciences company for $14.5 million on July 1, 2025, and holding 75 million shares in collaborator Orbital Therapeutics, which Bristol Myers Squibb agreed to acquire in October 2025 for $1.5 billion.
Company News
Beam Therapeutics Appoints Eric Foster as Chief Commercial Officer
Beam Therapeutics to Participate in Upcoming September 2026 Investor Conferences
4 Gene-Editing Biotech Stocks Worth Watching for Long-Term Gains
BEAM's Q2 Loss Wider Than Expected, Revenues Fall Y/Y, Pipeline in Focus
Beam Therapeutics Inc. (BEAM) Reports Q2 Loss, Lags Revenue Estimates
Beam Therapeutics Reports Second Quarter 2026 Financial Results and Announces First Patient Dosed in Global Pivotal Cohort of BEAM-302 Trial in Alpha-1 Antitrypsin Deficiency (AATD)
Beam Therapeutics: A Valuation With Upside Left
Beam Therapeutics to Present Updated Data from Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) in Late-Breaking Oral Presentation at the European Respiratory Society (ERS) Congress 2026
Beam Therapeutics Inc. (NASDAQ:BEAM) Given Average Rating of “Moderate Buy” by Brokerages
Amova Asset Management Americas Inc. Has $91.16 Million Stock Holdings in Beam Therapeutics Inc. $BEAM
Cathie Wood Is Buying This Up-and-Coming Biotech Stock. Should You Follow Her Lead?
Prime Medicine Beats Beam Therapeutics In Patent Dispute - But Both Are Investable
Prime Medicine Secures Favorable Arbitration Ruling in Beam Therapeutics Case
A New CRISPR "DNA Shredder" Could Change Gene-Editing -- What It Means for CRISPR Therapeutics
Powder Keg Stocks: 10 Most‑Shorted Names Primed For A Monster Squeeze
BEAM Stock Gains 5% as FDA Clears BEAM-304 IND for Phenylketonuria
Beam Therapeutics Announces Clearance of Investigational New Drug Application for BEAM-304 for the Treatment of Phenylketonuria (PKU) by the United States (U.S.) Food and Drug Administration
The Healthcare M&A Wave
Beam Therapeutics Stock Soars 21% in Three Months: Here's Why
3 Promising Genomics & Synthetic Biology Stocks in Spotlight in 2026